Meta-Analysis of Differential miRNA Expression after Bariatric Surgery

Langi, Gladys; Szczerbiński, Łukasz; Krętowski, Adam

doi:10.3390/jcm8081220

Cited by 29 publications

(20 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 27 ] Multiple studies showed decreased expression of miR-106b following bariatric surgery. [ 28 ] MiR-106b is associated with GLUT4 expression and translocation in response to insulin-induced glucose uptake in skeletal muscle. [ 29 ] In vitro studies of human adipocyte differentiation showed consistent changes in expression of miR-106b in mature adipocytes compared to their precursors, and miR-106b targets genes located in pathways associated with adipocyte differentiation.…”

Section: Discussionmentioning

confidence: 99%

Circulating MicroRNAs predict glycemic improvement and response to a behavioral intervention

et al. 2021

View full text Add to dashboard Cite

Background MicroRNAs may be important regulators of risk for type 2 diabetes. The purpose of this longitudinal observational study was to assess whether circulating microRNAs predicted improvements in fasting blood glucose, a major risk factor for type 2 diabetes, over 12 months. Methods The study included participants (n = 82) from a previously completed trial that tested the effect of restorative yoga on individuals with prediabetes. Circulating microRNAs were measured using a flow cytometry miRNA assay. Linear models were used to determine the optimal sets of microRNA predictors overall and by intervention group. Results Subsets of microRNAs were significant predictors of final fasting blood glucose after 12-months (R2 = 0.754, p < 0.001) and changes in fasting blood glucose over 12-months (R2 = 0.731, p < 0.001). Three microRNAs (let-7c, miR-363, miR-374b) were significant for the control group only, however there was no significant interaction by intervention group. Conclusions Circulating microRNAs are significant predictors of fasting blood glucose in individuals with prediabetes. Among the identified microRNAs, several have previously been associated with risk for type 2 diabetes. This is one of the first studies to use a longitudinal design to assess whether microRNAs predict changes in fasting blood glucose over time. Further exploration of the function of the microRNAs included in these models may provide new insights about the complex etiology of type 2 diabetes and responses to behavioral risk reduction interventions. Trial registration This study was a secondary analysis of a previously completed clinical trial that is registered at clinicaltrials.gov (NCT01024816) on December 3, 2009.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating MicroRNAs predict glycemic improvement and response to a behavioral intervention

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Exposure to HDL has previously been linked with epigenetic changes in microRNA in a number of differing cell types [ 56 ], but this is the first report of the impact of these (apo)lipoproteins in an in vitro human beta cell model; equally, a number of microRNA sequences have been linked with (dys)function of beta cells [ 28 ]. Examination of these literature, compared with the microchip array reported here ( Figure 4 ) reveal some common sequences [ 28 , 47 , 48 , 55 , 56 , 57 , 58 ]. For example, miR-21 has been shown to target Snc2, decreasing Vamp2 and GSIS, but also to significantly modulate apoptosis in a range of rodent and human islet cell lines and tissues [ 28 , 48 , 49 ].…”

Section: Discussionmentioning

confidence: 89%

Protection against Glucolipotoxicity by High Density Lipoprotein in Human PANC-1 Hybrid 1.1B4 Pancreatic Beta Cells: The Role of microRNA

Tarlton

Lightbody

Patterson

et al. 2021

Biology

View full text Add to dashboard Cite

High-density lipoproteins provide protection against the damaging effects of glucolipotoxicity in beta cells, a factor which sustains insulin secretion and staves off onset of type 2 diabetes mellitus. This study examines epigenetic changes in small non-coding microRNA sequences induced by high density lipoproteins in a human hybrid beta cell model, and tests the impact of delivery of a single sequence in protecting against glucolipotoxicity. Human PANC-1.1B4 cells were used to establish Bmax and Kd for [3H]cholesterol efflux to high density lipoprotein, and minimum concentrations required to protect cell viability and reduce apoptosis to 30mM glucose and 0.25 mM palmitic acid. Microchip array identified the microRNA signature associated with high density lipoprotein treatment, and one sequence, hsa-miR-21-5p, modulated via delivery of a mimic and inhibitor. The results confirm that low concentrations of high-density lipoprotein can protect against glucolipotoxicity, and report the global microRNA profile associated with this lipoprotein; delivery of miR-21-5p mimic altered gene targets, similar to high density lipoprotein, but could not provide sufficient protection against glucolipotoxicity. We conclude that the complex profile of microRNA changes due to HDL treatment may be difficult to replicate using a single microRNA, findings which may inform current drug strategies focused on this approach.

show abstract

“…Overall, in a meta-analysis of 17 studies evaluating the differential expression of microRNA before and after bariatric surgery both in humans and in animal models, several microRNAs were reported to be consistently down-regulated (miR-93-5p, miR-106b-5p, let-7b-5p, let-7i-5p, miR-16-5p, miR-19b-3p, miR-92a-3p, miR-222-3p, miR-142-3p, miR-140-5p, miR-155-5p, miR-320-3p) or up-regulated (miR-7-5p and miR-320c), with high concordance between studies [ 103 ]. However, it is worth highlighting that marked differences between the selected studies have emerged (i.e.…”

Section: Micrornas and Weight Loss: Evidence From Bariatric Surgery Intervention Studiesmentioning

confidence: 85%

Tissue and circulating microRNAs as biomarkers of response to obesity treatment strategies

Catanzaro

Filardi

Sabato

et al. 2020

J Endocrinol Invest

View full text Add to dashboard Cite

Background Obesity, characterized by an increased amount of adipose tissue, is a metabolic chronic alteration which has reached pandemic proportion. Lifestyle changes are the first line therapy for obesity and a large variety of dietary approaches have demonstrated efficacy in promoting weight loss and improving obesity-related metabolic alterations. Besides diet and physical activity, bariatric surgery might be an effective therapeutic strategy for morbid obese patients. Response to weight-loss interventions is characterised by high inter-individual variability, which might involve epigenetic factors. microRNAs have critical roles in metabolic processes and their dysregulated expression has been reported in obesity. Aim The aim of this review is to provide a comprehensive overview of current studies evaluating changes in microRNA expression in obese patients undergoing lifestyle interventions or bariatric surgery. Results A considerable number of studies have reported a differential expression of circulating microRNAs before and after various dietary and bariatric surgery approaches, identifying several candidate biomarkers of response to weight loss. Significant changes in microRNA expression have been observed at a tissue level as well, with entirely different patterns between visceral and subcutaneous adipose tissue. Interestingly, relevant differences in microRNA expression have emerged between responders and non-responders to dietary or surgical interventions. A wide variety of dysregulated microRNA target pathways have also been identified, helping to understand the pathophysiological mechanisms underlying obesity and obesity-related metabolic diseases. Conclusions Although further research is needed to draw firm conclusions, there is increasing evidence about microRNAs as potential biomarkers for weight loss and response to intervention strategies in obesity.

show abstract

Meta-Analysis of Differential miRNA Expression after Bariatric Surgery

Cited by 29 publications

References 88 publications

Circulating MicroRNAs predict glycemic improvement and response to a behavioral intervention

Circulating MicroRNAs predict glycemic improvement and response to a behavioral intervention

Protection against Glucolipotoxicity by High Density Lipoprotein in Human PANC-1 Hybrid 1.1B4 Pancreatic Beta Cells: The Role of microRNA

Tissue and circulating microRNAs as biomarkers of response to obesity treatment strategies

Contact Info

Product

Resources

About